Daily BriefsIndia

Daily Brief India: Tata Technologies, Adani Transmission, HPL Electric & Power, Mankind Pharma and more

In today’s briefing:

  • Tata Technologies Pre-IPO – The Positives – A Tata Group Listing After a Long Lull
  • Quiddity Leaderboard for BSE/​​SENSEX Jun 23: Six BSE 100 Changes and Four BSE 200 Changes
  • HPL Electric and Power Ltd- Forensic Analysis
  • Mankind Pharma IPO: The Bear Case

Tata Technologies Pre-IPO – The Positives – A Tata Group Listing After a Long Lull

By Sumeet Singh

  • Tata Technologies (TATATECH IN) (TT) is looking to raise around US$600m in its upcoming India IPO.
  • Tata Technologies is a global engineering services company offering product development and digital solutions, including turnkey solutions, to global original equipment manufacturers (OEMs) and their tier 1 suppliers. 
  • In this note we talk about the positive aspects of the deal.

Quiddity Leaderboard for BSE/​​SENSEX Jun 23: Six BSE 100 Changes and Four BSE 200 Changes

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the Potential ADDs/DELs for the BSE SENSEX, 100, 200, and 500 Indices in the June 2023 Rebalance.
  • There are only few more days left in the reference period used for the constituent selection process for the June 2023 Rebalance.
  • Currently, I see 6 ADDs/DELs for the BSE 100 index and 4 ADDs/DELs for the BSE 200 index.

HPL Electric and Power Ltd- Forensic Analysis

By Nitin Mangal

  • HPL Electric & Power (HPLE IN) is one of the key players in domestic electric meters market and domestic on-load, change-over switches market. The company also manufactures LED products.
  • Forensic overview of the company indicates poor capital allocation in the past, along with cash generation issues.
  • One must also keep a note of the inherent credit risk, as well as some interesting line items such as software and designs, on the balance sheet.

Mankind Pharma IPO: The Bear Case

By Arun George

  • Mankind Pharma (6596876Z IN), a pharmaceutical company, is seeking to raise up to Rs45 billion (US$550 million) in April, according to press reports.
  • In Mankind Pharma IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
  • The key elements of the bear case rest on worrying recent developments, FCF burn, rise in inventory days and a steady decline in RoCE.   

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars